Peptide LibraryPentadeca Arginate
Pentadeca Arginate is a research peptide in the Wound Healing / Cytoprotective class. The peptide sequence is the same as BPC-157, so the proposed mechanism is the same: angiogenic signalling through VEGFR2 and FAK pathways, modulation of the nitric oxide system, and cytoprotective effects on gastrointestinal mucosa reported in animal models.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
Vendor price snapshot
Each vendor's price is the median price per mg of its own listings; with fewer than 3 vendors there is no typical range. From public vendor listings collected in Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 2
- Listed offers
- 2
- Price per mg
- $4.40/mg
Research summary
Arginate salt form of the BPC-157 pentadecapeptide, marketed as a more stable alternative to the acetate salt. Not FDA-approved. Published research on the arginate form specifically is minimal; nearly all available evidence concerns BPC-157 itself.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Pentadeca Arginate profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Pentadeca Arginate dosage: no established human dose
Pentadeca arginate (PDA) has no established human dosage. It is sold as a form of BPC-157, described as its arginate salt, and no human study, animal study or registered trial of pentadeca arginate itself has been found. The few human reports that exist are for BPC-157 and are not evidence for this product.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: No study of pentadeca arginate itself has been published. Its proposed activity is borrowed from BPC-157, whose roughly 200 publications are mostly rodent studies from a small number of research groups. Whether the arginate form behaves like the acetate form used in BPC-157 research has not been tested, and no comparison of the two has been published.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| BPC-157 (analog evidence, not pentadeca arginate) — NCT02637284, phase 1, status unknown, no resultsClinical trial · Phase 1 trial of BPC-157, an analog of this product; registry status unknownStudied an analog, not Pentadeca Arginate itself | Healthy volunteers (n=42, estimated) | BPC-157 (Bepecin, PCO-02) 1, 3 or 6 tablets of 1 mg as a single dose; then 3 tablets every 8 hours | Oral | Single dose (phase 1a); every 8 hours (phase 1b) | Single dose, then 2 weeks | Safety and pharmacokinetics; no results posted | NCT02637284 — PCO-02 Safety and Pharmacokinetics Trial |
| BPC-157 (analog evidence, not pentadeca arginate) — Lee and Padgett 2021, uncontrolled knee pain chart reviewClinical trial · Retrospective single-clinic chart review of BPC-157, an analog of this product; uncontrolledStudied an analog, not Pentadeca Arginate itself | Patients with knee pain of mixed causes (16 of 17 reached by phone; 12 received BPC-157 alone, 4 with thymosin beta-4) | Not stated in the indexed abstract; see the BPC-157 profile | Intra-articular | Injection into the knee | Follow-up varied; most injections were 6 months to 1 year before the survey | 11 of 12 given BPC-157 alone reported significant improvement in knee pain, by phone survey with no specific measurement tools and no control group | Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. |
Where sources disagree
- BPC-157 evidence is not evidence for pentadeca arginate. Sellers describe PDA as a more stable salt form, but no published study confirms its composition, stability or behaviour in the body.
- BPC-157 itself has no established human dosage; its small human studies are reviewed on the BPC-157 profile.
Reconstitution
Common research vial sizes: 10 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 10 mg | 2 mL | 5 mg/mL | 50 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Science
Mechanism of Action
The peptide sequence is the same as BPC-157, so the proposed mechanism is the same: angiogenic signalling through VEGFR2 and FAK pathways, modulation of the nitric oxide system, and cytoprotective effects on gastrointestinal mucosa reported in animal models. The arginate counter-ion is claimed to improve stability in solution, but comparative pharmacokinetic data between the salt forms has not been published.
Studies
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide (class-level)
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (class-level)
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (class-level evidence)
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (class-level evidence)
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing (class-level evidence)
Regulatory & research status
Pentadeca Arginate is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Research status | Research-only compound; no approval pathway listed |
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
—
Pentadeca Arginate side effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Pentadeca Arginate: frequently asked questions
What is Pentadeca Arginate?
Arginate salt form of the BPC-157 pentadecapeptide, marketed as a more stable alternative to the acetate salt. Not FDA-approved. Published research on the arginate form specifically is minimal; nearly all available evidence concerns BPC-157 itself.
How does Pentadeca Arginate work?
The peptide sequence is the same as BPC-157, so the proposed mechanism is the same: angiogenic signalling through VEGFR2 and FAK pathways, modulation of the nitric oxide system, and cytoprotective effects on gastrointestinal mucosa reported in animal models. The arginate counter-ion is claimed to improve stability in solution, but comparative pharmacokinetic data between the salt forms has not been published.
Is Pentadeca Arginate FDA approved?
No. Pentadeca Arginate is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to Pentadeca Arginate?
Compounds most often compared with Pentadeca Arginate include BPC-157, TB-500 (Thymosin Beta-4 fragment), Thymosin β4 (Tβ4) and GHK-Cu (Copper Peptide). They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Parent-compound evidence — Multifunctionality and Possible Medical Application of the BPC 157 Peptide. Pharmaceuticals, 2025External reference
- Parent-compound evidence — Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing, 2025External reference
- Class-level evidence — Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — HSS J, 2025External reference
- Class-level evidence — Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain — Altern Ther Health Med, 2021External reference
- Class-level evidence — Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing — Cell Tissue Res, 2019External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This Pentadeca Arginate profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Pentadeca Arginate research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →